Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-TNF-α monoclonal antibody

Infliximab

Brand names: Remicade, Inflectra, Remsima, Flixabi, Zessly

Infliximab is a chimeric anti-TNF-alpha monoclonal antibody given by intravenous infusion (with a subcutaneous formulation also available). It is used in inflammatory arthritis, inflammatory bowel disease, psoriasis and related immune-mediated conditions.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds and neutralises soluble and membrane-bound tumour necrosis factor alpha, blocking a key pro-inflammatory cytokine and reducing inflammation.

Prescribing in practice

  • Screen for latent tuberculosis, hepatitis B and active infection before starting, as anti-TNF therapy can reactivate tuberculosis and serious infection.
  • Avoid in moderate to severe heart failure, as anti-TNF agents can worsen it.
  • Avoid live vaccines during treatment and review the patient's vaccination status beforehand.

Monitoring

Monitor for infection, infusion reactions and, where clinically indicated, full blood count and liver function during therapy.

Counselling the patient

  • Report fever, night sweats, persistent cough or weight loss, which may signal infection or tuberculosis.
  • Seek urgent help for breathing difficulty, rash or other symptoms during or shortly after an infusion.
  • Tell other healthcare professionals you are taking a biologic that suppresses the immune system.

Evidence & guidelines

NICE recommends anti-TNF therapy including infliximab for several immune-mediated inflammatory diseases within specified criteria.

Reference: NICE TA163/TA329/TA199; BSR guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways